EXTL3 mutations cause skeletal dysplasia, immune deficiency, and developmental delay.

We studied three patients with severe skeletal dysplasia, T cell immunodeficiency, and developmental delay. Whole-exome sequencing revealed homozygous missense mutations affecting exostosin-like 3 (EXTL3), a glycosyltransferase involved in heparan sulfate (HS) biosynthesis. Patient-derived fibroblasts showed abnormal HS composition and altered fibroblast growth factor 2 signaling, which was rescued by overexpression of wild-type EXTL3 cDNA. Interleukin-2-mediated STAT5 phosphorylation in patients' lymphocytes was markedly reduced. Interbreeding of the extl3-mutant zebrafish (box) with Tg(rag2:green fluorescent protein) transgenic zebrafish revealed defective thymopoiesis, which was rescued by injection of wild-type human EXTL3 RNA. Targeted differentiation of patient-derived induced pluripotent stem cells showed a reduced expansion of lymphohematopoietic progenitor cells and defects of thymic epithelial progenitor cell differentiation. These data identify EXTL3 mutations as a novel cause of severe immune deficiency with skeletal dysplasia and developmental delay and underline a crucial role of HS in thymopoiesis and skeletal and brain development

Recent Developments in Magnetically Coupled Vane Pumps for Tritium Service

Despite advances in shaft sealing, a totally reliable shaft seal for two-stage vane pumps has never been developed. Therefore, the magnetically coupled vane pump drive was developed to solve the critical problem of tritium leakage at the shaft seals of vane pumps. As a result, radioactive contamination of the work area and loss of valuable material can now be prevented

Jak3 deficiency blocks innate lymphoid cell development

Loss-of-function mutations in the tyrosine kinase JAK3 cause autosomal recessive severe combined immunodeficiency (SCID). Defects in this form of SCID are restricted to the immune system, which led to the development of immunosuppressive JAK inhibitors. We find that the B6.Cg-Nr1d1tm1Ven/LazJ mouse line purchased from Jackson Laboratories harbors a spontaneous mutation in Jak3, generating a SCID phenotype and an inability to generate antigen-independent professional cytokine-producing innate lymphoid cells (ILCs). Mechanistically, Jak3 deficiency blocks ILC differentiation in the bone marrow at the ILC precursor and the pre-NK cell progenitor. We further demonstrate that the pan-JAK inhibitor tofacitinib and the specific JAK3 inhibitor PF-06651600 impair the ability of human intraepithelial ILC1 (iILC1) to produce IFN-γ, without affecting ILC3 production of IL-22. Both inhibitors impaired the proliferation of iILC1 and ILC3 and differentiation of human ILC in vitro. Tofacitinib is currently approved for the treatment of moderate-to-severely active rheumatoid arthritis. Both tofacitinib and PF-06651600 are currently in clinical trials for several other immune-mediated conditions. Our data suggest that therapeutic inhibition of JAK may also impact ILCs and, to some extent, underlie clinical efficacy

Jak3 deficiency blocks innate lymphoid cell development

Loss-of-function mutations in the tyrosine kinase JAK3 cause autosomal recessive (AR) severe combined immunodeficiency (SCID). Defects in this form of SCID are restricted to the immune system, which led to the development of the immunosuppressive JAK inhibitors. We find that the B6.Cg-Nr1d1tm1Ven/LazJ mouse line purchased from Jackson Laboratories harbors a spontaneous mutation in Jak3 generating a SCID phenotype, with an inability to generate antigen-independent professional cytokine-producing innate lymphoid cells (ILCs). Mechanistically, Jak3 deficiency blocks ILC differentiation in the bone marrow at the ILC progenitor (ILCP) and the pre-NK cell progenitor (pre-NKP). We further demonstrate that the pan-JAK inhibitor tofacitinib and specific JAK3 inhibitor PF-06651600 impair the ability of human intraepithelial ILC1 (iILC1) to produce IFN-γ, without affecting ILC3 production of IL-22. Both inhibitors impaired the proliferation of iILC1 and ILC3 and differentiation of human ILC in vitro. Tofacitinib is currently approved for the treatment of moderate-to-severely active rheumatoid arthritis (RA) and is under clinical trial for several other immune-mediated conditions. Our data suggests that therapeutic inhibition of JAK may also impact ILCs and, to some extent, underlie clinical efficacy

N-WASP is required for B-cell-mediated autoimmunity in Wiskott-Aldrich syndrome.

Mutations of the Wiskott-Aldrich syndrome gene (WAS) are responsible for Wiskott-Aldrich syndrome (WAS), a disease characterized by thrombocytopenia, eczema, immunodeficiency, and autoimmunity. Mice with conditional deficiency of Was in B lymphocytes (B/WcKO) have revealed a critical role for WAS protein (WASP) expression in B lymphocytes in the maintenance of immune homeostasis. Neural WASP (N-WASP) is a broadly expressed homolog of WASP, and regulates B-cell signaling by modulating B-cell receptor (BCR) clustering and internalization. We have generated a double conditional mouse lacking both WASP and N-WASP selectively in B lymphocytes (B/DcKO). Compared with B/WcKO mice, B/DcKO mice showed defective B-lymphocyte proliferation and impaired antibody responses to T-cell-dependent antigens, associated with decreased autoantibody production and lack of autoimmune kidney disease. These results demonstrate that N-WASP expression in B lymphocytes is required for the development of autoimmunity of WAS and may represent a novel therapeutic target in WAS

Techno-economic analysis of a local district heating plant under fuel flexibility and performance

Brovst is a small district in Denmark. This paper analyses the use of local renewable resources in the district heating systems of Brovst. The present use of fossil fuels in the Brovst district heating plant (DHP) represents an increasing environmental and climate-related load. Therefore, an investigation has been made to reduce the use of fossil fuels for district heating system and make use of the local renewable resources (biogas, solar, and heat pump) for district heating purposes. In this article, the techno-economic assessment is achieved through the development of a suite of models that are combined to give cost and performance data for this district heating system. Local fuels have been analyzed for different perspectives to find the way to optimize the whole integrated system in accordance with fuel availability and cost. This paper represents the energy system analysis mode, energyPRO, which has been used to analyze the integration of a large-scale energy system into the domestic district heating system. A model of the current work on the basis of information from the Brovst plant (using fossil fuel) is established and named as a reference option. Then, four other options are calculated using the same procedure according to the use of various local renewable fuels known as “biogas option,” “solar option,” “heat pump option,” and “imported heat option.” A comparison has been made between the reference option and other options. The greatest reduction in heat cost is obtained from the biogas option by replacing a new engine, where 66 % of the current fuel is substituted with biogas.<br/